Correction: *The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial*

Ejiri K, Miyoshi T, Nakamura K, *et al*. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial. *BMJ Open* 2019;9:e026590. doi: 10.1136/bmjopen-2018-026590.

This article was previously published with an error.

Under 'Finding' section, the authors have stated, "This study is funded by Novartis Pharmaceuticals (Basel, Switzerland)."

The correct sentence is as follows:

"This study is funded by Novartis Pharma K. K."

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2019;9:e026590corr1. doi:10.1136/bmjopen-2018-026590corr1